Trial · NCT06344403
Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain
NCT06344403, Not applicable, Active not recruiting, Beijing Tiantan Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain. Trials, record NCT06344403. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06344403
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain
- NCT number
- NCT06344403
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 136 participants, estimated
- Lead sponsor
- Beijing Tiantan Hospital
- Conditions
- Herpes Zoster, Local Infiltration, Acute Pain
- Interventions
- analgesic, Tender point infiltration
- First posted
- 2024-04-03
- Last updated
- 2025-09-05
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The presence of postherpetic neuralgia using VAS score | 12 months | 12 months after the treatments, number of patients with any pain with a VAS score of higher than 0/Number of all patients，0="no pain" and 10="worst pain imaginable" |
| Secondary | visual analogue scale score at each time point | before the treatment (baseline), 30min after the intervention (for TPI group), then 1 day, 2 weeks, 1 month, 3 months, 6 months and 12 months following the treatment | 0 = 'no pain at all' to 10 = 'worst pain imaginable' |
| Secondary | Proportion of patients receiving repeated TPIs and block points | 12 months | Number of patients receiving TPI treatments more than twice/Number of all patients |
| Secondary | Consumption of oral drugs at each time point | day 1, then 2 weeks, 1 month, 3 months, 6 months and 12 months following the treatment. | Dose of celecoxib, pregabalin and tramadol |
| Secondary | The presence of PHN at month 3 and month 6 post treatment | 3 and 6 months after treatments | Number of patients with any pain with a VAS score of higher than 0/Number of all patients (0 = 'no pain at all' to 10 = 'worst pain imaginable') |
| Secondary | Patient satisfaction scores on the 5-point Likert scale | day 1, then week 2, month 1, month 3, month 6 and month 12 following the treatment | 1: Very dissatisfied,2: Dissatisfied,3: Not sure,4: Satisfied,5: Very satisfied |
| Secondary | Quality of life on the Scores on the WHOQOL-BREF | day 1, then week 2, month 1, month 3, month 6 and month 12 following the treatment | Scores on the WHOQOL-BREF. The responses are given on 5-point Likert scale (1-5) and the overall score ranges from 0 to 100; a higher score corresponds to better QoL. |
| Secondary | Adverse reactions through study completion | After treatments | Any side effect and uncomfortable situation related to treatment through study completion，an average of 1 year |
| Secondary | Predictive factors for the prevention of PHN at month 12 posttreatment | month 12 posttreatment | the correlation between patients' baseline characteristics and the incidence of PHN will be analyzed 12 months after treatment in TPI group. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06344403
GET https://conductscience.org/api/trials/v1/NCT06344403/registered